The DOI matches its OpenAlex record; 71 of the 71 references it cites were found in a registry or an index.
Oral naltrexone maintenance treatment for opioid dependence
Open accessAbstract
BACKGROUND: Research on clinical application of oral naltrexone agrees on several things. From a pharmacological perspective, naltrexone works. From an applied perspective, the medication compliance and the retention rates are poor. OBJECTIVES: To evaluate the effects of naltrexone maintenance treatment versus placebo or other treatments in preventing relapse in opioid addicts after detoxification. SEARCH STRATEGY: We searched: Cochrane Central Register of Controlled Trials (CENTRAL - The Cochrane Library issue 6 2010), PubMed (1973- June 2010), CINAHL (1982- June 2010). We inspected reference lists of relevant articles and contacted pharmaceutical producers of naltrexone, authors and other Cochrane review groups. SELECTION CRITERIA: All randomised controlled clinical trials which focus on the use of naltrexone maintenance treatment versus placebo, or other treatments to reach sustained abstinence from opiate drugs DATA COLLECTION AND ANALYSIS: Three reviewers independently assessed studies for inclusion and extracted data. One reviewer carried out the qualitative assessments of the methodology of eligible studies using validated checklists. MAIN RESULTS: Thirteen studies, 1158 participants, met the criteria for inclusion in this review.Comparing naltrexone versus placebo or no pharmacological treatments, no statistically significant difference were noted for all the primary outcomes considered. The only outcome statistically significant in favour of naltrexone is re incarceration, RR 0.47 (95%CI 0.26-0.84), but results come only from two studies. Considering only studies were patients were forced to adherence a statistical significant difference in favour of naltrexone was found for retention and abstinence, RR 2.93 (95%CI 1.66-5.18).Comparing naltrexone versus psychotherapy, in the two considered outcomes, no statistically significant difference was found in the single study considered.Naltrexone was not superior to benzodiazepines and to buprenorphine for retention and abstinence and side effects. Results come from single studies. AUTHORS' CONCLUSIONS: The findings of this review suggest that oral naltrexone did not perform better than treatment with placebo or no pharmacological agent with respect to the number of participants re-incarcerated during the study period. If oral naltrexone is compared with other pharmacological treatments such as benzodiazepine and buprenorphine, no statistically significant difference was found. The percentage of people retained in treatment in the included studies is however low (28%). The conclusion of this review is that the studies conducted have not allowed an adequate evaluation of oral naltrexone treatment in the field of opioid dependence. Consequently, maintenance therapy with naltrexone cannot yet be considered a treatment which has been scientifically proved to be superior to other kinds of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622
Bero, L. A., Grilli, R., Grimshaw, J. M., Harvey, E., Oxman, A. D., & Thomson, M. A. (1998) · BMJ · doi:10.1136/bmj.317.7156.465 · Cited by 2,396
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Self-citationMethadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Self-citationCHALMERS, I. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb26345.x · Cited by 561
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Self-citationRole of maintenance treatment in opioid dependence
Ward, J., Hall, W., & Mattick, R. P. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05356-2 · Cited by 424
Methadone maintenance at different dosages for opioid dependence
Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002208 · Cited by 406
Naltrexone, an Antagonist for the Treatment of Heroin Dependence: Effects in Man
Martin, W. R. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750360022003 · Cited by 392
Methadone at tapered doses for the management of opioid withdrawal
Amato, L., Davoli, M., Minozzi, S., Ferroni, E., Ali, R., & Ferri, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003409.pub4 · Cited by 222
Self-citationNaltrexone pharmacotherapy for opioid dependent federal probationers
Cornish, J. W., Metzger, D., Woody, G. E., Wilson, D., McLellan, A. T., Vandergrift, B., & O'Brien, C. P. (1997) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(97)00020-2 · Cited by 215
Studies of EN-1639A (Naltrexone): A New Narcotic Antagonist
RESNICK, R. B., VOLAVKA, J., FREEDMAN, A. M., & THOMAS, M. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.6.646 · Cited by 197
Pharmacologic Treatment of Heroin-Dependent Patients
O'Connor, P. G., & Fiellin, D. A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00008 · Cited by 183
Sustained-Release Naltrexone For Opioid Dependence
Lobmaier, P. P. K., Kornør, H., Kunøe, N., & Bjørndal, A. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006140.pub2 · Cited by 126
Operant analysis of human heroin self-administration and the effects of naltrexone.
Mello, N. K., Mendelson, J. H., Kuehnle, J. C., & Sellers, M. S. (1981) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32374-8 · Cited by 106
Naltrexone for heroin dependence treatment in St. Petersburg, Russia
Krupitsky, E. M., Zvartau, E. E., Masalov, D. V., Tsoi, M. V., Burakov, A. M., Egorova, V. Y., Didenko, T., Romanova, T. N., Ivanova, E. B., Bespalov, A., et al. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.02.002 · Cited by 103
(1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770270085008 · Cited by 103
LAAM maintenance vs methadone maintenance for heroin dependence
Clark, N. C., Lintzeris, N., Gijsbers, A. J., Whelan, G., Dunlop, A. J., Ritter, A. J., & Ling, W. W. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002210 · Cited by 102
Behavioral Therapy to Augment Oral Naltrexone for Opioid Dependence: A Ceiling on Effectiveness?
Nunes, E. V., Rothenberg, J. L., Sullivan, M. A., Carpenter, K. M., & Kleber, H. D. (2006) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990600918973 · Cited by 100
Schottenfeld, R. S., Chawarski, M. C., & Mazlan, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60954-x · Cited by 99
Methadone at tapered doses for the management of opioid withdrawal
Amato, L., Davoli, M., Minozzi, S., Ali, R. L., & Ferri, M. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003409.pub3 · Cited by 95
Self-citationKrupitsky, E. M., Zvartau, E. E., Masalov, D. V., Tsoy, M. V., Burakov, A. M., Egorova, V. Y., Didenko, T. Y., Romanova, T. N., Ivanova, E. B., Bespalov, A. Y., et al. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.05.005 · Cited by 93
Naltrexone-induced dysphoria in former opioid addicts
Crowley, T. J., Wagner, J., Zerbe, G. O., & Macdonald, M. (1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.9.1081 · Cited by 93
Clonidine and opiate receptor antagonists in the treatment of heroin addiction
Gerra, G., Marcato, A., Caccavari, R., Fontanesi, B., Delsignore, R., Affini, G. F., Avanzini, P., Rustichelli, P., & Passeri, M. (1995) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(94)00077-8 · Cited by 90
Rothenberg, J. L., Sullivan, M. A., Church, S. H., SERACINI, A. M., Collins, E. D., Kleber, H. D., & Nunes, E. V. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00301-x · Cited by 85
The efficacy of naltrexone in preventing reabuse of heroin after detoxification
Shufman, E., Porat, S., Witztum, E., Gandacu, D., Bar‐Hamburger, R., & Ginath, Y. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91240-8 · Cited by 84
Ling, W. W., & Wesson, D. R. (1984) · PubMed · Cited by 83
Naltrexone in addicted business executives and physicians.
Washton, A. M., Pottash, A. L. C., & Gold, M. S. (1984) · PubMed · Cited by 83
Clinical Experience with Naltrexone
O'brien, C. P., Greenstein, R. A., Mintz, J., & Woody, G. E. (1975) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952997509005662 · Cited by 82
Follow‐up after a six‐month maintenance period on naltrexone versus placebo in heroin addicts
SAN, L., POMAROL, G., Peri, J., OLLE, J. M., & Camı́, J. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01859.x · Cited by 78
Naltrexone: a clinical perspective.
Greenstein, R. A., Arndt, I., McLellan, A. T., O'Brien, C. P., & Evans, B. (1984) · PubMed · Cited by 75
Clinical experience with naltrexone in suburban opioid addicts.
Tennant, F. S., Rawson, R. A., Aj, C., & Mann, A. (1984) · PubMed · Cited by 69
Naltrexone treatment of heroin addiction: Efficacy and safety in a double-blind dosage comparison
Judson, B. A., Carney, T. M., & Goldstein, A. (1981) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(81)90049-1 · Cited by 66
Multiple family therapy and naltrexone in the treatment of opiate dependence
Anton, R. F., Hogan, I., Jalali, B., Riordan, C. E., & Kleber, H. D. (1981) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(81)90110-1 · Cited by 60
Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.
Preston, K. L., & Bigelow, G. E. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10212-7 · Cited by 60
Raby, W. N., Carpenter, K. M., Rothenberg, J. L., Brooks, A. C., Jiang, H., Sullivan, M. A., Bisaga, A. M., Comer, S. D., & Nunes, E. V. (2009) · American Journal on Addictions · doi:10.1080/10550490902927785 · Cited by 57
Naltrexone treatment in a jail work-release program.
Brahen, L. S., Henderson, R. K., Capone, T., & Kordal, N. (1984) · PubMed · Cited by 55
Naltrexone maintenance treatment for opioid dependence
Kirchmayer, U., Davoli, M., & Verster, A. D. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001333 · Cited by 47
Self-citationAddiction Pharmacotherapy 2000: New Options, New Challenges
Rawson, R. A., McCann, M., Hasson, A. L., & Ling, W. W. (2000) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2000.10400238 · Cited by 44
Craving in Heroin Addicts Maintained on the Opiate Antagonist Naltrexone
Sideroff, S. I., Charuvastra, V. C., Jarvik, M. E., & Ouren, J. (1978) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952997809007017 · Cited by 43
The Treatment of Heroin Addiction: Naltrexone Alone and with Behavior Therapy
Callahan, E. J., Rawson, R. A., McCleave, B., Arias, R., Glazer, M., & Liberman, R. P. (1980) · International Journal of the Addictions · doi:10.3109/10826088009040057 · Cited by 41
Brahen, L. S. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220063007 · Cited by 40
Naltrexone treatment of heroin addiction: One-year follow-up
Judson, B. A., & D, A. G. M. (1984) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(84)90003-6 · Cited by 38
Naltrexone treatment of opiate-dependent persons
Hollister, L. E., Schwin, R. L., & Kasper, P. (1977) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(77)90027-8 · Cited by 37
Altman, J. L., Meyer, R. E., Mirin, S. M., Mcnamee, H. B., & Mcdougle, M. (1976) · International Journal of the Addictions · doi:10.3109/10826087609056165 · Cited by 37
Short-term effects of naltrexone in 155 heroin ex-addicts.
Volavka, J., Resnick, R. B., Kestenbaum, R. S., & Freedman, A. M. (1976) · PubMed · Cited by 37
A naltrexone double blind placebo controlled study in Israel.
Lerner, A., Sigal, M., Bacalu, A., Shiff, R., Burganski, I., & Gelkopf, M. (1992) · PubMed · Cited by 36
A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence
Rea, F., Bell, J. R., Young, M. R., & Mattick, R. P. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.02.003 · Cited by 35
Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts
Navaratnam, V., Jamaludin, A., Raman, N., Mohamed, M., & Mansor, S. M. (1994) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(94)90161-9 · Cited by 33
Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients
Stella, L., D'Ambra, C., Mazzeo, F., Capuano, A., Franco, F. D., Avolio, A., & Ambrosino, F. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.036 · Cited by 31
Psychosocial factors in outcome in two opiate addiction treatments
Grey, C. C., Osborn, E., & Reznikoff, M. (1986) · Journal of Clinical Psychology · doi:10.1002/1097-4679(198601)42:1<185::aid-jclp2270420132>3.0.co;2-w · Cited by 29
Methadyl Acetate (LAAM) in the Treatment of Heroin Addicts
Judson, B. A. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790070024003 · Cited by 24
Narcotic Antagonist Treatment: Clinical Experience with Naltrexone
Lewis, D. C., Mayer, J. E., Hersch, R. G., & Black, R. (1978) · International Journal of the Addictions · doi:10.3109/10826087809039316 · Cited by 23
Naltrexone and Behavior Therapy for Heroin Addiction
Rawson, R. A., Glazer, M., Callahan, E. J., & Liberman, R. P. (1979) · PsycEXTRA Dataset · doi:10.1037/e497382006-005 · Cited by 21
Curran, S. F., & Savage, C. (1976) · PsycEXTRA Dataset · doi:10.1037/e497452006-012 · Cited by 19
Guo, S., Jiang, Z., & Wu, Y. (2001) · Hong Kong journal of psychiatry · Cited by 18
Psychosocial Adjustment, Modality Choice, and Outcome in Naltrexone versus Methadone Treatment
Osborn, E., Grey, C. C., & Reznikoff, M. (1986) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998609016877 · Cited by 15
Five-year follow-up of opiate addicts with naltrexone and behavior therapy.
Rawson, R. A., & Tennant, F. S. (1984) · PsycEXTRA Dataset · doi:10.1037/e473622004-001 · Cited by 14
Experiences with Naltrexone in Buffalo
Taintor, Z. C., Landsberg, R., Wicks, N., Plumb, M. M., D'Amanda, C., & Greenwood, J. (1975) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952997509005664 · Cited by 13
Varying Clinical Contexts for Administering Naltrexone
Hurzeler, M., Gerwirtz, D., & Kleber, H. D. (1976) · PsycEXTRA Dataset · doi:10.1037/e497452006-011 · Cited by 13
Brahen, L. S., Capone, T. A., Heller, R. C., Linden, S. L., Landy, H. J., & Lewis, M. J. (1978) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952997809028001 · Cited by 10
Ladewig, D. (1990) · PubMed · Cited by 9
Abstinence treatments for opiate addicts: Therapeutic community or naltrexone?
Arndt, I., McLellan, A. T., & O’Brien, C. P. (1984) · PsycEXTRA Dataset · doi:10.1037/e471442004-001 · Cited by 7
Grinenko, A. I., Krupitskiĭ, E. M., & Zvartau, E. E. (2003) · PubMed · Cited by 6
The Double-Blind Crossover Trial Design: How Good Is It for Psychoactive Drugs?
Brahen, L. S., Capone, T. A., & Wojak, J. C. (1979) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952997909007044 · Cited by 5
Pw, J. (1990) · PubMed · Cited by 5
D’Ippoliti, D., Davoli, M., Bargagli, A. M., Pasqualini, F., & Ca, P. (1996) · PubMed · Cited by 3
Self-citation
Research works printed but not linked: 1
- Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org · DOI · Paper page
Cited by
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
Global patterns of opioid use and dependence: harms to populations, interventions, and future action
Degenhardt, L., Grebely, J., Stone, J., Hickman, M., Vickerman, P., Marshall, B. D. L., Bruneau, J., Altice, F. L., Henderson, G., Rahimi-Movaghar, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32229-9 · Cited by 832
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Metadata
- Authors
- Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. D.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2011-02-16
- Issue
- 4
- Pages
- CD001333-CD001333
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2140341041
- Cited by
- 419
- References
- 71
- Type
- reference entry
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.